Current research predominantly spike protein.
Welcome to P3 Diagnostics
P3 Diagnostics, LLC (“P3”) serves to foster the business development of technology created under the direction of Benjamin Larimer, PhD, and The Larimer Lab.
In March 2020, Dr. Larimer sought to utilize his knowledge of peptides to develop a method of antibody detection for COVID-19 in the human body. In July 2020, a provisional patent was issued.
There are many participants in this testing environment, but our technology is different. This is because rather than using widely available antigens to capture antibodies, Larimer has used his technology to map exactly where a patient's antibodies bind to COVID19. This precision provides a type of “facial recognition” that will maximize sensitivity and specificity, when the rest of the industry is using satellite imaging to identify COVID19 immunity.
P3, in conjunction with Larimer and the University of Alabama-Birmingham, is exploring the different paths which can bring this assay to market most efficiently to create value for those who need an accurate at-home antibody test.
Would you like to contact us today?
Meet Our Team
Dr. Benjamin LarimerCo-Founder
F.H. "Joe" GayCo-Founder
Meet Our Advisors
Eric LeeBoard of Managers
Eric has been involved in P3 Diagnostics since its pre-formation discussions, and he currently serves on the Board of Managers in a director and non-attorney advisory role. Eric is an experienced attorney, advisor, and director with a diverse background ranging from military service to Chief Legal Officer. His current roles outside of P3 include Chief Legal Officer, Chief Compliance Officer, Data Privacy Officer, Corporate Secretary, and board roles for a multinational company, as well as board roles for other for-profit and not-for-profit companies. Throughout his career, he has served as a lead advisor for founders, family offices, public and private boards, CEOs, CLOs, management teams, operating partners, and others throughout the corporate lifecycle. He brings a practical approach to growth and development and overall management based on a solid understanding of operational and commercial requirements.
You can learn more about Eric here: https://www.linkedin.com/in/sericlee/
Dr. Garima ArvikarAdvisor
Dr. Garima Arvikar is a protein engineer currently working as a Postdoctoral Fellow at the University of Alabama at Birmingham in the laboratory of Dr. Benjamin Larimer. Garima received her PhD in biochemistry from The University of Alabama in Dec 2015. Following completion of her degree, she held a postdoctoral fellowship at McMaster University in the laboratory of Dr. Eric Brown where she worked antimicrobial drug discovery. Her current research focuses on the discovery and engineering of novel single domain antibodies for targeted cancer therapy using phage display technology.
Mike is an advisor and key contributor to the phage analysis. He is a multidimensional database expert with over 25 years of experience in the software industry. He holds an MBA from Illinois State University.
Dr. Larimer has been given the Innovator Award from NIH
Project Title: Site-Specific Immune Cell Activation Detection for Improving Individualized Cancer Immunotherapy
Grant ID: DP2-CA261453
Funded by the National Cancer Institute
NIH to support 85 new grants featuring high-risk, high-reward research
- National Institutes of Health (NIH)
The 2020 Director’s Awards will feature highly innovative biomedical research by investigators at all career stages.
Structure of 2019-nVCoV
It has been noted that some CoVs do not need to have the full ensemble of structural proteins to make virions.
Limitations of sequencing based diagnostic tests
● Do not detect immune response
● Can't monitor duration of response
Serological assays (Our Technology)
● Detect past infection
● Antibody based long-term immunity
● Possibility of transfusions as treatment
● Vaccine development
● Interactions of host antibody with pathogen / antigen / epitope
● 2019-nCoV-highly infectious
● Recombinant spike protein, specific and labor intensive
● Epitope, non-infectious and small sequences capable of detecting immune response
Don't hesitate to get touch please fill out this form
and we'll get back to you as soon as possible.